JP Morgan analyst Kenneth Worthington upgrades Blackstone (NYSE:BX) from Neutral to Overweight and raises the price target from $104 to $105.
Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment In Phase 3 REBUILD Study For INOpulse In Fibrotic Interstitial Lung Disease; Company Expects To Report Top-Line Results From This Study In Mid-2023
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today
